Anzeige
Mehr »
Login
Montag, 06.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Bevorstehende News könnten diesen Kupfer-Explorer ins große Rampenlicht katapultieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
169 Leser
Artikel bewerten:
(1)

Signant Health Names Krishna Maridi, a Finance Leader with Over 25 Years of Experience, as Chief Financial Officer

Finanznachrichten News

PHILADELPHIA, Dec. 11, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment of Krishna Maridi as chief financial officer. A finance executive with over 25 years' experience working with US-based and global healthcare organizations, Maridi's industry knowledge and track record of driving business transformation made him the ideal choice to lead Signant's financial strategy and financial operations.

Krishna Maridi, Chief Financial Officer, Signant Health

Maridi joins Signant from Sonrava Health where he served as chief financial officer and executive vice president. Prior to that role, he was US chief financial officer at Galderma and before that vice president of finance at PPD, where he played a pivotal role in the company's sale to Thermo Fisher Scientific. Earlier in his career, Maridi had a two-decade tenure at Pfizer where he progressed from a management trainee to executive leadership positions, developing extensive expertise in financial planning, business transformation, and strategic growth initiatives.

"I've had the benefit of first-hand experience watching Krishna lead through complex process improvement to make a business operate better for its customers and employees," commented Roger Smith, Signant's chief executive officer. "In an environment where our biopharma and CRO customers seek partners that enable greater precision in service delivery based on analytics, his unique combination of pharmaceutical industry knowledge, broad financial expertise, and global business acumen will be a lever in our growth and market leadership."

"I am honored to join Signant as CFO during this dynamic period of growth fueled by the adoption of digital clinical solutions," said Maridi. "As the industry embraces digital transformation, sponsors and CROs seek partners with a proven track record in evidence generation and operational excellence. I look forward to building on Signant's strong financial foundation to deliver enduring solutions that support the clinical trials of today and tomorrow."

To learn more about Signant Health and its full range of eClinical solutions, visit: https://www.signanthealth.com/

About Signant Health
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes - including all Top 20 pharma - have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.

Contact:
Heather Bilinski
media@signanthealth.com

Photo - https://mma.prnewswire.com/media/2578366/Krishna_Maridi.jpg
Logo - https://mma.prnewswire.com/media/1202052/Signant_Health_Logo.jpg

Signant Health Logo

Cision View original content:https://www.prnewswire.co.uk/news-releases/signant-health-names-krishna-maridi-a-finance-leader-with-over-25-years-of-experience-as-chief-financial-officer-302328288.html

© 2024 PR Newswire
6 Richtige für 2025
Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.